With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...

Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...

Patients taking 100-miligram doses of Viking’s VK2735 lost 8.2% of their body weight after 28 days, or 6.8% more than those taking a placebo, and no patients taking the highest dose stopped ...

ByInvesting.com • Oct 25, 2024 Viking Therapeutics stock holds Buy rating with focus on upcoming oral VK2735 data at Obesity Week On Thursday, BTIG maintained a Buy rating on Viking Therapeutics ...

Similar adverse events as those seen with other GLP-1 receptor agonists were reported. The Company is also evaluating an oral tablet formulation of VK2735 (ClinicalTrials.gov Identifier: NCT05203237).

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

At the Stifel Healthcare Conference, Thryv Therapeutics will present key updates on its precision medicine approach, targeting novel treatments for Long QT Syndrome, heart failure and atrial ...

Unicef's representative in Pakistan issued a stark warning about the severe health risks posed by hazardous air quality in Punjab, impacting over 11 million children. The alarming pollution levels ...

Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeekHigh Quality Obesity Management by Targeting the CRF2 Receptor: Enhanced Fat Loss with Lean Mass ...